Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation.
BACKGROUND: Lesions of cutaneous lupus erythematosus (CLE) are refractory to a wide range of topical or systemic therapies. The pathogenesis of CLE is multifactorial and polygenic, and many of its details remain unclear. However, immunologic evidence suggests the possible therapeutic use of tacrolim...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 64; no. 4; pp. 337 - 342 |
|---|---|
| Autores principales: | , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
Apr2008
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105650100&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105650100 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Apr2008 vid: 64 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 105650100 2009819067 10.1007/s00228-007-0421-2 NLM18157526 105650100 ppf: 337 ppct: 5 formats: fmt: @attributes: type: P tig: atl: Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. aug: au: Tzellos TG Kouvelas D affil: Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. sug: subj: Administration, Transcutaneous Antibiotics Therapeutic Use Lupus Erythematosus, Cutaneous Therapy Medical Practice, Evidence-Based Databases Human ab: BACKGROUND: Lesions of cutaneous lupus erythematosus (CLE) are refractory to a wide range of topical or systemic therapies. The pathogenesis of CLE is multifactorial and polygenic, and many of its details remain unclear. However, immunologic evidence suggests the possible therapeutic use of tacrolimus and pimecrolimus. CLE is one of the most common dermatological autoimmune disorders worldwide, which includes systemic lupus erythematosus (SLE) with malar rash, subacute cutaneous lupus erythematosus (SCLE) and discoid lupus erythematosus (DLE). OBJECTIVE: Our aim was to determine the efficacy of topical pimecrolimus and tacrolimus in the treatment of cutaneous lupus erythematosus. METHODS: The literature was systematically reviewed. Medline, Embase, and the Cochrane Database were searched for systemic reviews, randomised controlled trials and nonrandomised clinical trials using the search terms 'pimecrolimus', 'Elidel', 'SDZ ASM 981', 'tacrolimus', 'Protopic', 'FK506' and 'cutaneous lupus erythematosus'. Studies were assessed independently by two authors. RESULTS: Five studies were eligible for inclusion in this review. Only one of them was a randomised controlled trial (RCT). There was no significant difference between tacrolimus and clobetasol; however, evidence indicates the highest tolerability of tacrolimus compared with corticosteroids. This review indicates the efficacy of tacrolimus and pimecrolimus in, at least initial, cutaneous lesions of SLE. However, in SCLE and DLE lesions, the efficacy appears to be lower, perhaps due to the chronicity of those lesions. CONCLUSION: The lack of RCTs is characteristic. Future studies should focus on efficacy, short- and long-term effects and cost-effectiveness. However, tacrolimus and pimecrolimus show efficacy, and such effort is worthwhile. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|